Comparison of the Antifibrotic Efficacy of the Pan-Histone 
Deacetylase-Inhibitor Panobinostat Versus the IPF-Drug Pirfenidone in 
Fibroblasts from Patients with Idiopathic Pulmonary Fibrosis

Korfei, M.; Stelmaszek, D.; Skwarna, S.; Chillappagari, S.; Bach, A. C.; MacKenzie, B.; Ruppert, C.; Saito, S.; Mahavadi, P.; Klepetko, W.; Fink, L.; Seeger, W.; Lasky, J. A.; Pullamsetti, S. S.; Kraemer, O.; Guenther, A.

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Comparison of the Antifibrotic Efficacy of the Pan-Histone Deacetylase-Inhibitor Panobinostat Versus the IPF-Drug Pirfenidone in Fibroblasts from Patients with Idiopathic Pulmonary Fibrosis

MPS-Authors

/persons/resource/persons224334

Seeger, W.
Lung Development and Remodeling, Max Planck Institute for Heart and Lung Research, Max Planck Society;

/persons/resource/persons224324

Pullamsetti, S. S.
Lung Development and Remodeling, Max Planck Institute for Heart and Lung Research, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Korfei, M., Stelmaszek, D., Skwarna, S., Chillappagari, S., Bach, A. C., MacKenzie, B., et al. (2018). Comparison of the Antifibrotic Efficacy of the Pan-Histone Deacetylase-Inhibitor Panobinostat Versus the IPF-Drug Pirfenidone in Fibroblasts from Patients with Idiopathic Pulmonary Fibrosis. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 197.

Cite as: https://hdl.handle.net/21.11116/0000-0004-5C83-1

Abstract

There is no abstract available